Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study
The Lancet Haematology2015Vol. 3(1), pp. e12–e21
Citations Over TimeTop 1% of 2015 papers
Walter Ageno, LG Mantovani, Sylvia Haas, Reinhold Kreutz, Danja Monje, Jonas Schneider, Martin van Eickels, Martin Gebel, Elizabeth R. Zell, Alexander G.G. Turpie
Related Papers
- → Treatment of Proximal Deep-Vein Thrombosis With the Oral Direct Factor Xa Inhibitor Rivaroxaban (BAY 59-7939)(2007)340 cited
- → Rivaroxaban in the Treatment of PICC-associated Upper Extremity Venous Thrombosis(2017)31 cited
- → Rivaroxaban for Thromboprophylaxis in Patients with Antiphospholipid Syndrome(2017)1 cited
- Effects of rivaroxaban and fondaparinux on clotting assays(2008)
- → Faculty Opinions recommendation of Oral rivaroxaban for symptomatic venous thromboembolism.(2011)